NASDAQ:XON - Intrexon Stock Price, Forecast & News

Intrexon trades on the NASDAQ under the ticker symbol "XON."

Intrexon Corp (NASDAQ:XON) announced its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.05. The biotechnology company had revenue of $35.99 million for the quarter, compared to analysts' expectations of $29.62 million. Intrexon had a negative return on equity of 45.51% and a negative net margin of 393.13%. The business's revenue for the quarter was down 20.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.51) earnings per share. View Intrexon's Earnings History.

Intrexon is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Intrexon.

3 Wall Street analysts have issued 1-year price objectives for Intrexon's stock. Their forecasts range from $6.00 to $43.00. On average, they anticipate Intrexon's stock price to reach $19.67 in the next year. This suggests a possible upside of 360.6% from the stock's current price. View Analyst Price Targets for Intrexon.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intrexon in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intrexon.

News stories about XON stock have been trending neutral on Sunday, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intrexon earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Intrexon.

Some companies that are related to Intrexon include Anavex Life Sciences (AVXL), Eloxx Pharmaceuticals (ELOX), Geovax Labs (GOVX), HedgePath Pharmaceuticals (HPPI) and Redpoint Bio (RPBC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intrexon investors own include Nordic American Tanker (NAT), ZIOPHARM Oncology (ZIOP), Hess (HES), Boeing (BA), Opko Health (OPK), Celldex Therapeutics (CLDX), Gilead Sciences (GILD), TherapeuticsMD (TXMD), Alibaba Group (BABA) and Bausch Health Companies (BHC).

Intrexon's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Third Security LLC (46.42%), State Street Corp (2.27%), Sumitomo Mitsui Trust Holdings Inc. (1.92%), Nikko Asset Management Americas Inc. (1.92%), Jacobs Levy Equity Management Inc. (0.67%) and First Eagle Investment Management LLC (0.50%). Company insiders that own Intrexon stock include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Joel D Liffman, Nir Nimrodi, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Institutional Ownership Trends for Intrexon.

XON stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Wellington Shields Capital Management LLC, Rafferty Asset Management LLC, Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Cubist Systematic Strategies LLC, Goldman Sachs Group Inc. and Bank of America Corp DE. Company insiders that have sold Intrexon company stock in the last year include Donald P Lehr, Helen Sabzevari, Jeffrey Thomas Perez, Randal J Kirk, Rick L Sterling, Robert F Walsh III, Thomas Bostick and Thomas D Reed. View Insider Buying and Selling for Intrexon.

XON stock was acquired by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Third Security LLC, ARK Investment Management LLC, Iridian Asset Management LLC CT, Alpine Global Management LLC, California Public Employees Retirement System, Russell Investments Group Ltd. and Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Intrexon.

Shares of XON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of XON stock can currently be purchased for approximately $4.27.

Intrexon has a market capitalization of $694.66 million and generates $160.57 million in revenue each year. The biotechnology company earns $-509,340,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. View Additional Information About Intrexon.

The official website for Intrexon is http://www.dna.com/.

Intrexon's mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company can be reached via phone at 301-556-9900 or via email at [email protected]